Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) saw a significant decline in short interest in February. As of February 15th, there was short interest totalling 398,700 shares, a decline of 17.2% from the January 31st total of 481,400 shares. Based on an average trading volume of 669,500 shares, the short-interest ratio is currently 0.6 days.
Separately, HC Wainwright reiterated a "buy" rating and issued a $25.00 target price on shares of Milestone Pharmaceuticals in a research note on Friday, February 28th.
Check Out Our Latest Stock Analysis on MIST
A number of hedge funds and other institutional investors have recently made changes to their positions in MIST. Toronto Dominion Bank purchased a new position in Milestone Pharmaceuticals during the 4th quarter valued at $1,770,000. Boxer Capital Management LLC bought a new position in Milestone Pharmaceuticals in the fourth quarter worth $729,000. Virtu Financial LLC purchased a new position in Milestone Pharmaceuticals during the fourth quarter valued at $170,000. XTX Topco Ltd purchased a new position in Milestone Pharmaceuticals during the fourth quarter valued at $80,000. Finally, BML Capital Management LLC increased its stake in shares of Milestone Pharmaceuticals by 3.0% in the 3rd quarter. BML Capital Management LLC now owns 1,136,091 shares of the company's stock worth $1,727,000 after acquiring an additional 33,196 shares in the last quarter. Institutional investors own 86.18% of the company's stock.
Shares of MIST stock traded up $0.34 during mid-day trading on Wednesday, reaching $1.98. The stock had a trading volume of 2,219,210 shares, compared to its average volume of 894,526. The stock's 50-day moving average price is $2.05 and its two-hundred day moving average price is $1.77. The firm has a market capitalization of $105.59 million, a PE ratio of -2.44 and a beta of 1.80. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18. Milestone Pharmaceuticals has a 52-week low of $1.12 and a 52-week high of $2.75.
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Milestone Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.
While Milestone Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.